American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
Memorial Sloan Kettering Cancer Center · Cornell University
Abstract
The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management of individuals with an inherited susceptibility to cancer are core elements of oncology care. ASCO released its first statement on genetic testing in 1996 and updated that statement in 2003 and 2010 in response to developments in the field. In 2014, the Cancer Prevention and Ethics Committees of ASCO commissioned another update to reflect the impact of advances in this area on oncology practice. In particular, there was an interest in addressing the opportunities and challenges arising from the application of massively parallel sequencing-also known as next-generation sequencing-to cancer susceptibility…
Citation impact
- FWCI
- 73.45
- Percentile
- 100%
- References
- 101
Authors
10- MEMark E. RobsonCorresponding
Memorial Sloan Kettering Cancer Center, Cornell University
- ARAngela R. Bradbury
Memorial Sloan Kettering Cancer Center, Cornell University
- BABanu Arun
Memorial Sloan Kettering Cancer Center, Cornell University
- SMSusan M. Domchek
Memorial Sloan Kettering Cancer Center, Cornell University
- JMJames M. Ford
Memorial Sloan Kettering Cancer Center, Cornell University
Topics & keywords
- Medicine
- Genetic testing
- Cancer genetics
- Cancer
- Oncology
- Clinical Oncology
- Massive parallel sequencing
- Germline mutation